We previously reported that some biomarkers, such as human kallikreins 6 and 10 (KLK6 and KLK10) are consistently elevated in about 2–5% of pancreatic cancer sera, at 100% specificity,21 leading us to query if such biomarkers have any role to play in clinical practice. This evidence concerns the gene KLK6 and pancreatic neoplasm.